Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Proofpoint Expects Pricing IPO In $10-$12/Shr Range - Quick Facts

RELATED NEWS
Trade PFPT now with 

Proofpoint, Inc. said it estimates pricing the initial public offering of its common stock in a range between $10.00 and $12.00 per share.

The company is selling 5 million shares of common stock and the selling stockholders identified in this prospectus are selling 1.199 million shares of common stock. Proofpoint said it will not receive any of the proceeds from the sale of shares of common stock by the selling stockholders.

Prior to this offering, there has been no public market for the company's common stock. Proofpoint has applied to list its common stock on the NASDAQ Global Market under the symbol "PFPT."

The underwriters have the option to purchase from the company a maximum of 750 thousand additional shares and from the selling stockholders a maximum of 179,914 additional shares to cover over-allotments of shares.

Click here to receive FREE breaking news email alerts for Proofpoint, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Computer and printer maker Hewlett-Packard Co. (HPQ) said Wednesday after the markets closed that its third quarter profit fell 29% from last year, hurt mainly by higher restructuring charges even as revenue grew 1%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue beat analysts' forecast. Stocks fluctuated over the course of the trading day on Wednesday before ending the session mostly higher. The Dow and the S&P 500 both finished the day in positive territory, although the tech-heavy Nasdaq posted a modest loss. President Barack Obama spoke harshly of the terrorist group allegedly responsible for the execution of American freelance journalist James Foley in a statement on Wednesday. Obama described the group known as the Islamic State of Iraq and the Levant, or ISIL, as a cancer that needs to be extracted.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.